All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Results from a phase II, non-randomized, open-label, single-arm study (PembroWM; NCT03630042) evaluating efficacy and safety of pembrolizumab, a PD-1 inhibitor, and rituximab combination therapy in the treatment of relapsed/refractory (R/R) Waldenstrom's macroglobulinemia (WM) were published by Kothari et al.1 in British Journal of Haematology. |
Key learnings: |
A total of 17 patients were included; 88% of patients were pretreated with covalent Bruton’s tyrosine kinase inhibitors (cBTKi) and 71% were refractory/intolerant to cBTKi. |
The primary endpoint was not met as overall response was only achieved in 7 patients (very good partial response, 1; partial response, 3; minor response, 3) at Week 24.
|
Median progression-free survival (PFS) was 13.6 months; 1- and 2-year PFS rates were 58.2% and 19.4%, respectively. |
Median overall survival (OS) was not reached; 1- and 2-year OS rates were 92.9% and 67%, respectively. |
The 1- and 2-year time to next treatment rates were 72.7% and 43.1%, respectively. |
Adverse events (AEs) were observed in 94% of patients.
|
There were no significant improvements in quality-of-life scores in the majority of patients, except for emotional (p = 0.02) and cognitive functioning (p = 0.03). |
The results indicate that the combination of pembrolizumab and rituximab is feasible and tolerable in patients with R/R WM, including those who have been heavily pretreated and are refractory to cBTKi. Further research is needed to explore the modulation of PD-1 axis in the management of WM. |
‘The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom’s macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.
This initiative is funded by Cellectar Biosciences and Eli Lilly. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.’
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?